Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Erectile Dysfunction - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2015', provides an overview of the Erectile Dysfunction's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Erectile Dysfunction Overview 9 Therapeutics Development 10 Pipeline Products for Erectile Dysfunction - Overview 10 Pipeline Products for Erectile Dysfunction - Comparative Analysis 11 Erectile Dysfunction - Therapeutics under Development by Companies 12 Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes 14 Erectile Dysfunction - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Erectile Dysfunction - Products under Development by Companies 19 Erectile Dysfunction - Products under Investigation by Universities/Institutes 21 Erectile Dysfunction - Companies Involved in Therapeutics Development 22 Acorda Therapeutics, Inc. 22 Apricus Biosciences, Inc. 23 Aprogen, Inc. 24 Bioheart, Inc. 25 Biolab Sanus Farmaceutica Ltda. 26 Corridor Pharmaceuticals Inc. 27 Furiex Pharmaceuticals, Inc. 28 Futura Medical plc 29 Hanmi Pharmaceuticals, Co. Ltd. 30 IntelGenx Corp. 31 Mezzion Pharma Co. Ltd. 32 Mitsubishi Tanabe Pharma Corporation 33 NAL Pharmaceuticals Ltd. 34 Pacific Therapeutics Ltd. 35 Palatin Technologies, Inc. 36 Pharmicell Co., Ltd. 37 Sagene Pharmaceuticals, Inc. 38 Suda Ltd 39 Yungjin Pharm Ind. Co., Ltd. 40 Erectile Dysfunction - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Combination Products 42 Assessment by Target 43 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 AdipoCell - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 alprostadil - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AP-102 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 BL-214 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 cimaglermin alfa - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 dapoxetine hydrochloride - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 HCP-1302 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 HCP-1303 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Immpocellgram - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 MED-2002 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Next Generation Melanocortin Receptor IV Agonist - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 PL-6983 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 selegiline + PDE-5 Inhibitor - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 sildenafil citrate - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 sildenafil citrate - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 sildenafil citrate - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 T-6932 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 tadalafil - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 tadalafil - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 TPN-729 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 udenafil - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 YBH-1603 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Erectile Dysfunction - Recent Pipeline Updates 83 Erectile Dysfunction - Dormant Projects 94 Erectile Dysfunction - Discontinued Products 97 Erectile Dysfunction - Product Development Milestones 98 Featured News & Press Releases 98 Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product 98 Aug 28, 2012: Acorda Announces GGF2 Preclinical Data On Treatment Of Erectile Dysfunction 98 Jul 18, 2012: Zydus Urosciences Launches Udenafil For Treatment Of Erectile Dysfunction In India 99 Sep 08, 2011: Sagene Completes Pre-IND Meeting With FDA For Dual-Action Erectile Dysfunction Drug 99 Oct 12, 2010: Dong-A Launches Zydena For Daily Treatment Of Erectile Dysfunction In Korea 100 Sep 02, 2010: IntelGenx Achieves Positive Bioequivalence Results For Erectile Dysfunction Film Product 100 Nov 19, 2009: Once-A-Day Dosing Clinical Study Of Udenafil For Erectile Dysfunction Completed By Dong-A Pharmaceutical Co., Ltd. 100 Nov 11, 2009: ZYDENA Poised To Enter Global Market With Phase III Clinical Trial Starting For US FDA Approval 101 Sep 11, 2009: New Drug Udenafil By Dong-A PharmTech Co. Ltd For Erectile Dysfunction in US Trials 102 Aug 28, 2009: Dong-A Receives Approval For Zydena For Treatment Of Erectile Dysfunction 102 Appendix 103 Methodology 103 Coverage 103 Secondary Research 103 Primary Research 103 Expert Panel Validation 103 Contact Us 104 Disclaimer 104
List of Tables Number of Products under Development for Erectile Dysfunction, H1 2015 10 Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Investigation by Universities/Institutes, H1 2015 14 Comparative Analysis by Late Stage Development, H1 2015 15 Comparative Analysis by Clinical Stage Development, H1 2015 16 Comparative Analysis by Early Stage Development, H1 2015 17 Comparative Analysis by Unknown Stage Development, H1 2015 18 Products under Development by Companies, H1 2015 19 Products under Development by Companies, H1 2015 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2015 21 Erectile Dysfunction - Pipeline by Acorda Therapeutics, Inc., H1 2015 22 Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H1 2015 23 Erectile Dysfunction - Pipeline by Aprogen, Inc., H1 2015 24 Erectile Dysfunction - Pipeline by Bioheart, Inc., H1 2015 25 Erectile Dysfunction - Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 26 Erectile Dysfunction - Pipeline by Corridor Pharmaceuticals Inc., H1 2015 27 Erectile Dysfunction - Pipeline by Furiex Pharmaceuticals, Inc., H1 2015 28 Erectile Dysfunction - Pipeline by Futura Medical plc, H1 2015 29 Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 30 Erectile Dysfunction - Pipeline by IntelGenx Corp., H1 2015 31 Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H1 2015 32 Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 33 Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 34 Erectile Dysfunction - Pipeline by Pacific Therapeutics Ltd., H1 2015 35 Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H1 2015 36 Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H1 2015 37 Erectile Dysfunction - Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 38 Erectile Dysfunction - Pipeline by Suda Ltd, H1 2015 39 Erectile Dysfunction - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 40 Assessment by Monotherapy Products, H1 2015 41 Assessment by Combination Products, H1 2015 42 Number of Products by Stage and Target, H1 2015 44 Number of Products by Stage and Mechanism of Action, H1 2015 46 Number of Products by Stage and Route of Administration, H1 2015 48 Number of Products by Stage and Molecule Type, H1 2015 50 Erectile Dysfunction Therapeutics - Recent Pipeline Updates, H1 2015 83 Erectile Dysfunction - Dormant Projects, H1 2015 94 Erectile Dysfunction - Dormant Projects (Contd..1), H1 2015 95 Erectile Dysfunction - Dormant Projects (Contd..2), H1 2015 96 Erectile Dysfunction - Discontinued Products, H1 2015 97
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
